# A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

> **NCT02076412** · PHASE3 · COMPLETED · sponsor: **Rigel Pharmaceuticals** · enrollment: 74 (actual)

## Conditions studied

- Immune Thrombocytopenic Purpura

## Interventions

- **DRUG:** Fostamatinib Disodium
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02076412
- **Lead sponsor:** Rigel Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2019-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02076412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02076412, "A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02076412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*